Redeye: Hansa Biopharma - Ends 2024 on a soft note
10 februari, 09:20
10 februari, 09:20
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25.6m. Hansa does not expect to record any material provisions related to retroactive discounts after 2024. Hansa enters 2025 with a more significant number of centres using Idefirix and improved support from European experience, reimbursement and guidelines.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
10 februari, 09:20
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25.6m. Hansa does not expect to record any material provisions related to retroactive discounts after 2024. Hansa enters 2025 with a more significant number of centres using Idefirix and improved support from European experience, reimbursement and guidelines.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
SBB
Fonder
Inflation
Analys
Stenbeck-comebacken
SBB
Fonder
Inflation
Analys
Stenbeck-comebacken
1 DAG %
Senast
Bolåneräntor
Idag, 07:47
SBAB sänker sin rörliga boränta
OMX Stockholm 30
1 DAG %
Senast
2 517,96